Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.7464
-0.0211 (-2.75%)
At close: Jun 18, 2025, 4:00 PM
0.7522
+0.0058 (0.78%)
After-hours: Jun 18, 2025, 7:56 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
91
Market Cap
71.52M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IMUX News
- 10 days ago - Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted - Seeking Alpha
- 14 days ago - Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - PRNewsWire
- 16 days ago - Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - PRNewsWire
- 17 days ago - Immunic to Participate in Investor, Scientific and Industry Conferences in June - PRNewsWire
- 21 days ago - Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - PRNewsWire
- 22 days ago - Immunic, Inc. Announces Proposed Public Offering - PRNewsWire
- 6 weeks ago - Immunic to Participate in Scientific and Industry Conferences in May - PRNewsWire
- 7 weeks ago - Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial - PRNewsWire